MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
May 26, 2022

Bank of Nova Scotia (BNS, $65.35) beats Q2 earnings expectations

Bank of Nova Scotia beat second-quarter earnings expectations,  but projected  higher expenses and loan-loss provisions and slower mortgage growth, amidst rising inflation and interest rates.

Scotiabank’s  adjusted earnings came in at C$2.18 per share, handily topping expectations of C$1.96.

Canada’s third-biggest lender experienced more than 20% year-over-year increase in their Canadian businesses on the back of mortgages and commercial lending recovery. Its international business earnings surged +43% as provision for credit losses fell and margins increased.

Related Ticker: BNS

Momentum Indicator for BNS turns positive, indicating new upward trend

BNS saw its Momentum Indicator move above the 0 level on November 25, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 69 similar instances where the indicator turned positive. In of the 69 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BNS just turned positive on November 26, 2025. Looking at past instances where BNS's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BNS advanced for three days, in of 340 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 328 cases where BNS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BNS broke above its upper Bollinger Band on November 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BNS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 25, placing this stock slightly worse than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.605) is normal, around the industry mean (1.350). BNS has a moderately high P/E Ratio (18.606) as compared to the industry average of (12.452). Projected Growth (PEG Ratio) (1.638) is also within normal values, averaging (4.434). Dividend Yield (0.045) settles around the average of (0.040) among similar stocks. P/S Ratio (3.370) is also within normal values, averaging (3.474).

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), Wells Fargo & Co (NYSE:WFC), HSBC Holdings PLC (NYSE:HSBC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS), Bank of New York Mellon Corp (NYSE:BK).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 140.47B. The market cap for tickers in the group ranges from 1.04M to 852.29B. JPM holds the highest valuation in this group at 852.29B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was 3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 19%. ANZGF experienced the highest price growth at 11%, while ACGBF experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was -59%. For the same stocks of the Industry, the average monthly volume growth was -52% and the average quarterly volume growth was -67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 67
P/E Growth Rating: 33
Price Growth Rating: 45
SMR Rating: 10
Profit Risk Rating: 24
Seasonality Score: 17 (-100 ... +100)
View a ticker or compare two or three
BNS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. BNS showed earnings on August 26, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Profile
Fundamentals
Details
Industry
Major Banks
Address
1709 Hollis Street
Phone
+1 416 866-6161
Employees
89483
Web
https://www.scotiabank.com
Interact to see
Advertisement
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#investment#artificial_intelligence
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#artificial_intelligence#trading
Tickeron, a leader in AI-powered financial solutions, proudly announces the launch of its Double Agent Trading Bot, designed for trading Carpenter Technology Corporation (CRS) and Direxion Daily Semiconductor Bear 3x Shares (SOXS).
#artificial_intelligence
Apple Inc. (AAPL), a global leader in consumer electronics, continues to be a cornerstone of the technology sector, driving innovation and commanding significant market attention.
#artificial_intelligence
NVIDIA’s earnings on May 28 could jolt the tech sector. With market volatility rising, traders are turning to Tickeron’s AI Agent for real-time insights, predictive analytics, and dual-strategy trading tools to navigate potential price swings and seize market opportunities.
#artificial_intelligence
As the DOJ and FTC move to break up Google’s search dominance and impose AI investment oversight, the tech giant faces a pivotal legal battle that could reshape the digital and AI landscapes—creating major implications for investors, competitors, and consumers alike.
#artificial_intelligence
GameStop (GME) continues to captivate investors with its explosive volatility and strong retail sentiment. As AI tools highlight bullish signals and a possible breakout, traders weigh the risks of speculation against the potential rewards in May 2025.
#artificial_intelligence
Mastercard (MA) continues to impress investors with strong earnings, rising digital payments, and bullish AI-driven signals. Backed by robust financials and cutting-edge trading tools from Tickeron, MA stands out as a leader in the fintech space for 2025.
From Walmart's retail resilience to Exxon Mobil's energy strength, May 2025 highlights key market movers. Discover how Tickeron’s AI bots analyze WMT, IVW, COST, and XOM—uncovering trends, boosting trading strategies, and navigating market volatility with precision.
#trading#artificial_intelligence
A powerful recession signal is flashing red: the Leading/Lagging Ratio has plunged to levels not seen since 2008. As markets grow turbulent, smart investors are turning to Tickeron’s AI trading agents to spot opportunities and stay ahead of the downturn.
#trading#artificial_intelligence
AI trading bots are no longer just experimental—they’re outperforming traditional strategies. Discover how bots trading ITA, TSM, META, and others achieved over 40% annual returns and what this means for the future of investing.
FingerMotion (FNGR) is making waves in 2025 with a 52% stock surge, strategic AI expansion into Indonesia, and strong retail momentum. Learn how traders are using correlation analysis, inverse ETFs, and Tickeron’s AI tools to navigate FNGR’s dynamic moves.
#artificial_intelligence#trading
Ferrari (RACE) is accelerating in 2025 with a 25% YTD gain, strong earnings, and bullish momentum fueled by innovation and Lewis Hamilton’s F1 move. Discover how Tickeron’s AI tools help traders capitalize on this luxury stock’s high-performance potential.
Intel’s stock is down 64%, but a bold turnaround under new CEO Lip-Bu Tan and the upcoming 18A chip rollout could spark a rebound. This article explores Intel’s financials, strategic shifts, and how AI tools from Tickeron help traders navigate the volatility.
#artificial_intelligence
Dogecoin (DOGE) fell 12.78% in five days, rattled by whale activity, Musk headlines, and ETF rumors. Is a breakout coming—or more downside? Explore key trends, technical levels, and how Tickeron’s AI bots help traders navigate DOGE’s next move.
The week of June 2-6, 2025, saw financial markets demonstrate resilience amid U.S.-China trade tensions and key economic data releases.
Tesla, Inc. (TSLA), a global leader in electric vehicles (EVs) and artificial intelligence (AI)-driven technologies, has been a focal point for investors in 2025.
#artificial_intelligence#trading
As artificial intelligence continues to reshape the financial industry, AI-powered trading agents have emerged as influential tools in portfolio management and speculative trading.
#investment#artificial_intelligence
Amazon (NASDAQ: AMZN) remains a cornerstone of the technology and e-commerce sectors, consistently driving innovation and market influence.
#artificial_intelligence
ntroduction to Eli Lilly and Company (LLY) Eli Lilly and Company (LLY), a global pharmaceutical giant, has been a cornerstone of the healthcare sector since its founding in 1876. Headquartered in Indianapolis, Indiana, the company specializes in developing innovative treatments for diabetes, oncology, immunology, and neuroscience, with blockbuster drugs like Mounjaro and Zepbound driving significant…